MetaCap

Boundless Bio Inc. (BOLD)

NASDAQ: BOLDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.32-0.06 (-2.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BOLD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$54.78M
EPS (TTM)
-$2.46
52-week range
0.961 – 3.16
Day range
2.28 – 2.39
Volume / Avg
147.87K / 131.34K
Beta
—

52-week range

$0.961$3.16

BOLD stock today

On Nov 20, BOLD ended the session at $2.32, shedding $0.06 (2.52%), versus the S&P 500's 3.70% decline. Shares are 26.7% below their 52-week high of $3.16, set on Aug 24, 2026 and 141.4% above the 52-week low of $0.961, in the middle of the past year's range. BOLD is up 93.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 105.3%.

Boundless Bio has posted a net loss over the last twelve months (EPS of -$2.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Boundless Bio

Company profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
Headquarters
San Diego, CA
Employees
28
IPO year
2024

Financial highlights

Full financials

Boundless Bio reported a net loss of $58.2 million, compared with a loss of $65.4 million a year earlier. Diluted earnings per share came in at -$2.60.

Boundless Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-58.20M$-65.36M$-49.43M
EPS (diluted)$-2.60$-3.85$-40.65

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$4.00+72.41%

  • Strong buy 0
  • Buy 0
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.23 vs —

BOLD news

All BOLD news

Boundless Bio peers

Health Care sector
BOLD peer companies
CompanyPrice% ChgMarket capCompare
AZRAzora Therapeutics Inc.3.85-0.52%$55.00Mvs BOLD
XLOXilio Therapeutics Inc.7.56-1.11%$53.40Mvs BOLD
KZIAKazia Therapeutics Limited ADR4.92-8.38%$56.22Mvs BOLD
CTORCitius Oncology Inc.0.5035-10.95%$53.25Mvs BOLD
IBIOiBio Inc.0.8001-0.11%$56.37Mvs BOLD
XBITXBiotech Inc.1.73+2.98%$52.74Mvs BOLD
TENXTenax Therapeutics Inc.1.25-10.07%$56.92Mvs BOLD
LFVNLifevantage Corporation4.15-15.13%$52.63Mvs BOLD

Indexes, lists and sector

Boundless Bio stock FAQ

What is Boundless Bio's stock price today?

BOLD last traded at $2.32 as of Nov 20, 4:00 PM EST, down 2.52% on the day. Prices are delayed at least 15 minutes.

What is the BOLD 52-week high?

The 52-week high for BOLD is $3.16 and the 52-week low is $0.961. The stock is currently 26.7% below its high.

Compare BOLD